Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › HRS-7535 phase 2 (add-on to metformin + SGLT2i)

HRS-7535 phase 2 (add-on to metformin + SGLT2i)

HRS-7535 · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
HRS-7535
Population
t2d
Phase
2
Participants
53
Duration
16 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
HRS-7535 30 mgt2d china1651——−1.5 vs −0.40.0 vs 2.0—15.7 vs 2.013.7 vs 2.07.8 vs 0.0—verified
HRS-7535 60 mgt2d china1653——−2.4 % vs −0.7 %
estimand not specified
−1.8 vs −0.40.0 vs 2.0—21.2 vs 2.019.2 vs 2.03.8 vs 0.0—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (11)
  • HRS-7535 30 mg · ae_dc · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
    TEAEs leading to treatment discontinuation 1 (2.0) 0 0
  • HRS-7535 30 mg · nausea · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
    Nausea 1 (2.0) 8 (15.7) 11 (21.2)
  • HRS-7535 30 mg · vomiting · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
    Vomiting 1 (2.0) 7 (13.7) 10 (19.2)
  • HRS-7535 30 mg · sae · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
    Serious adverse events 0 4 (7.8) 2 (3.8)
  • HRS-7535 30 mg · hba1c · Abstract RESULTS
    placebo (n=51). At week 16, the least‑squares mean differences in HbA1c from baseline for the HRS-7535 30 mg, HRS-7535 60 mg and placebo groups were -16 mmol/mol (95% CI -19, -14) (-1.5% [95% CI -1.7, -1.3]), -20 mmol/mo
  • HRS-7535 60 mg · weight_unsp · Abstract RESULTS
    (6.5%) were 35.3%, 37.7% and 3.9%, respectively. Body weight loss was -2.4% in the HRS-7535 60 mg group vs -0.7% in the placebo group. Most treatment-emergent
  • HRS-7535 60 mg · ae_dc · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
    TEAEs leading to treatment discontinuation 1 (2.0) 0 0
  • HRS-7535 60 mg · nausea · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
    Nausea 1 (2.0) 8 (15.7) 11 (21.2)
  • HRS-7535 60 mg · vomiting · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
    Vomiting 1 (2.0) 7 (13.7) 10 (19.2)
  • HRS-7535 60 mg · sae · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
    Serious adverse events 0 4 (7.8) 2 (3.8)
  • HRS-7535 60 mg · hba1c · Abstract RESULTS
    placebo (n=51). At week 16, the least‑squares mean differences in HbA1c from baseline for the HRS-7535 30 mg, HRS-7535 60 mg and placebo groups were -16 mmol/mol (95% CI -19, -14) (-1.5% [95% CI -1.7, -1.3]), -20 mmol/mo

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HRS-7535 phase 2 (add-on to metformin + SGLT2i). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs-7535-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.